Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-09-23 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Final OS results reported for TROPION-Breast01
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and contains standard regulatory boilerplate language at the end, including a reference to RNS being approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. The content itself is a press release announcing clinical trial results (TROPION-Breast01) for a drug (datopotamab deruxtecan). This type of announcement, which is a formal regulatory disclosure but not a comprehensive financial report (like 10-K or IR) or a specific corporate action notice (like DIV or SHA), fits best under the general 'Regulatory Filings' category, which serves as the fallback for miscellaneous regulatory announcements not covered by more specific codes. Since it is a formal announcement distributed via RNS, RNS is the most appropriate classification.
2024-09-23 English
FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the FDA approval of FluMist for self-administration in the US, including background information, study results, and company statements. The document is not a full financial report, audit report, or earnings release. It is a regulatory filing providing material information to the SEC and investors but does not fit into categories like Annual Report, Interim Report, or Earnings Release. The length (9064 characters) and content indicate it is a substantive regulatory announcement rather than a brief report publication announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-09-20 English
FluMist approved for self-administration in US
Regulatory Filings Classification · 100% confidence The document is clearly identified as an 'RNS Number' release from AstraZeneca PLC, dated September 20, 2024. RNS stands for Regulatory News Service, which is a primary channel for official company announcements in the UK. The content announces a specific regulatory event: the FDA approval of FluMist for self-administration in the US. This type of material—a timely, material announcement disseminated via an official regulatory channel (RNS) that doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR)—is best classified as a general Regulatory Filing or Announcement. Since 'RNS' is explicitly mentioned as the source and the content is a material, non-financial-statement announcement, the most appropriate code is RNS, which serves as the general regulatory announcement fallback.
2024-09-20 English
FASENRA EGPA US FDA APPROVAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It provides detailed information about the FDA approval of Fasenra for a new indication (EGPA), including clinical trial data, drug information, and company background. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing that provides material information to investors but does not constitute a full financial report or presentation. The length (13,574 characters) and content indicate it is a substantive regulatory announcement rather than a brief notice or certification. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-18 English
Fasenra EGPA US FDA approval
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' header and is dated 18 September 2024. It announces a specific corporate event: the US FDA approval of Fasenra for a new indication (EGPA), supported by clinical trial data (MANDARA). This type of announcement, which is a material update disseminated via the Regulatory News Service (RNS) system, is typically classified as a general regulatory announcement or news release. Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific shareholder vote result (DVA), the most appropriate category is the general regulatory filing/announcement fallback, RNS. The length (14,729 chars) suggests it is a substantive announcement, not just a brief notification of publication (RPA).
2024-09-18 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by AstraZeneca PLC, reporting a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically the purchase of shares by the Non-Executive Chair of the Board. The content focuses on insider shareholding transactions, detailing the purchase of 2,000 ordinary shares. There is no financial report, earnings data, or management discussion. The document is a regulatory filing reporting insider share transactions, which corresponds to the category 'Director's Dealing' (DIRS). The document length is 4185 characters, which is consistent with a detailed insider transaction report rather than a brief announcement or a full financial report.
2024-09-13 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.